Latest Financial Performance News

Global Health Ltd reports stable revenue and a significant EBITDA improvement in H1 FY26, driven by a strategic shift to SaaS platforms and AI integration. The company’s partnership with Best Practice and upcoming Lifecard launch position it for growth in Australia’s digital healthcare sector.

FINEOS Corporation reports robust FY25 financial performance, driven by subscription revenue growth and embedded AI innovations, setting a confident outlook through FY27.

Novo Resources Corp. reported a net loss of CAD 22.4 million for 2025, slightly improving from the previous year, while securing a $5.9 million capital raise to support ongoing exploration and operations.

Synlait confirms the imminent sale of its North Island assets to Abbott for NZ$307 million, aiming to reset its balance sheet amid a challenging half-year result. The company unveils a recovery roadmap focused on stabilising and scaling its core operations.

Synlait Milk Limited has reported a significant half-year loss driven by manufacturing setbacks and market pressures, alongside a strategic recovery roadmap focused on asset sales and operational overhaul.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending December 2025, payable in April 2026. The dividend is fully unfranked, reflecting foreign income components.

Premier Investments reported a modest 0.38% rise in net profit from continuing operations for the half-year ending January 2026, alongside a 3% increase in revenue and a fully franked interim dividend of 45 cents per share.

CLINUVEL Pharmaceuticals reports record first-half profits and confirms CEO Philippe Wolgen’s leadership through a pivotal growth phase, prioritising its vitiligo program and Nasdaq ambitions.

Almonty Industries has commenced commercial production at its flagship Sangdong Mine in South Korea and secured more than US$200 million through Nasdaq IPO and equity offerings to fund expansion projects. Despite rising revenues driven by soaring tungsten prices, the company reported a significant net loss due to non-cash derivative liabilities.

SunRice Group maintains its forecast for profit growth in FY26, even as revenue is expected to remain flat or slightly decline due to competitive pressures, adverse weather, and geopolitical disruptions.

Austal Limited has addressed ASX concerns over its half-year financial report, confirming compliance with accounting standards despite a qualified audit opinion linked to US Department of Defense contractual relief revenue.